Serine and one-carbon metabolism in cancer

Nature Reviews Cancer

Volumn 16, Issue 10, 2016, Pages 650-662

  Yang, Ming ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FOLIC ACID; GLYCINE; METHIONINE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; THYMIDINE PHOSPHATE;

AMINO ACID SYNTHESIS; CARBON METABOLISM; CARCINOGENESIS; CELL STRESS; GENE AMPLIFICATION; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; CELL PROLIFERATION; METABOLISM; PATHOLOGY;

CELL PROLIFERATION; HUMANS; NEOPLASMS; SERINE;

EID: 84988431514     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.81     Document Type: Review

References (132)

1. Phillips, M. M., Sheaff, M. T., Szlosarek, P. W. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res. Treat. 45, 251-262 (2013).
2. Altman, B. J., Stine, Z. E., Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer https://dx.doi.org/10.1038/nrc.2016.71 (2016).
3. Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542-546 (2013).
4. Kalhan, S. C., Hanson, R. W. Resurgence of serine: an often neglected but indispensable amino acid. J. Biol. Chem. 287, 19786-19791 (2012).
5. Furuya, S. An essential role for de novo biosynthesis of l-serine in CNS development. Asia Pac. J. Clin. Nutr. 17 (Suppl. 1), 312-315 (2008).
6. De Koning, T. J., Klomp, L. W. Serine-deficiency syndromes. Curr. Opin. Neurol. 17, 197-204 (2004).
7. Yoshida, K. et al. Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality. J. Biol. Chem. 279, 3573-3577 (2004).
8. Jaeken, J. et al. 3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. J. Inherit. Metab. Dis. 19, 223-226 (1996).
9. Hart, C. E. et al. Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am. J. Hum. Genet. 80, 931-937 (2007).
10. Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040-1044 (2012).
11. Kalhan, S. C. et al. Metabolic and genomic response to dietary isocaloric protein restriction in the rat. J. Biol. Chem. 286, 5266-5277 (2011).
12. Sun, L. et al. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 25, 429-444 (2015).
13. Chaneton, B. et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458-462 (2012).
14. Ye, J. et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl Acad. Sci. USA 109, 6904-6909 (2012).
15. Hitosugi, T. et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22, 585-600 (2012).
16. Kung, C. et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19, 1187-1198 (2012).
17. Davis, S. R. et al. Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. Am. J. Physiol. Endocrinol. Metab. 286, E272-E279 (2004).
18. Allen, R. W., Moskowitz, M. Arrest of cell growth in the G1 phase of the cell cycle by serine deprivation. Exp. Cell Res. 116, 127-137 (1978).
19. Rowe, P. B., Sauer, D., Fahey, D., Craig, G., McCairns, E. One-carbon metabolism in lectin-activated human lymphocytes. Arch. Biochem. Biophys. 236, 277-288 (1985).
20. Brosnan, M. E., MacMillan, L., Stevens, J. R., Brosnan, J. T. Division of labour: how does folate metabolism partition between one-carbon metabolism and amino acid oxidation? Biochem. J. 472, 135-146 (2015).
21. Tibbetts, A. S., Appling, D. R. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 30, 57-81 (2010).
22. Vazquez, A., Markert, E. K., Oltvai, Z. N. Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS ONE 6, e25881 (2011).
23. Tedeschi, P. M. et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 4, e877 (2013).
24. Ducker, G. S. et al. Reversal of cytosolic one-carbon flux compensates for loss of the mitochondrial folate pathway. Cell Metab. 23, 1140-1153 (2016).
25. Nikkanen, J. et al. Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metab. 23, 635-648 (2016).
26. Pasternack, L. B., Laude, D. A. Jr & Appling, D. R. 13C NMR detection of folate-mediated serine and glycine synthesis in vivo in Saccharomyces cerevisiae. Biochemistry 31, 8713-8719 (1992).
27. Herbig, K. et al. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J. Biol. Chem. 277, 38381-38389 (2002).
28. Gregory, J. F. 3rd et al. Primed, constant infusion with [2H3]serine allows in vivo kinetic measurement of serine turnover, homocysteine remethylation, and transsulfuration processes in human one-carbon metabolism. Am. J. Clin. Nutr. 72, 1535-1541 (2000).
29. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298-302 (2014).
30. Tucker, E. J. et al. Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab. 14, 428-434 (2011).
31. Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 5, 3128 (2014).
32. Lewis, C. A. et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55, 253-263 (2014).
33. Zhao, H., French, J. B., Fang, Y., Benkovic, S. J. The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans. Chem. Commun. (Camb.) 49, 4444-4452 (2013).
34. Chan, C. Y. et al. Purinosome formation as a function of the cell cycle. Proc. Natl Acad. Sci. USA 112, 1368-1373 (2015).
35. French, J. B. et al. Spatial colocalization and functional link of purinosomes with mitochondria. Science 351, 733-737 (2016).
36. Girgis, S. et al. Molecular cloning, characterization and alternative splicing of the human cytoplasmic serine hydroxymethyltransferase gene. Gene 210, 315-324 (1998).
37. Suh, J. R., Herbig, A. K., Stover, P. J. New perspectives on folate catabolism. Annu. Rev. Nutr. 21, 255-282 (2001).
38. Field, M. S., Kamynina, E., Stover, P. J. MTHFD1 regulates nuclear de novo thymidylate biosynthesis and genome stability. Biochimie 126, 27-30 (2016).
39. Bao, X. R. et al. Mitochondrial dysfunction remodels one-carbon metabolism in human cells. eLife 5, e10575 (2016).
40. Stincone, A. et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol. Rev. Camb. Philos. Soc. 90, 927-963 (2015).
41. Liu, L. et al. Malic enzyme tracers reveal hypoxia-induced switch in adipocyte NADPH pathway usage. Nat. Chem. Biol. 12, 345-352 (2016).
42. Bolusani, S. et al. Mammalian MTHFD2L encodes a mitochondrial methylenetetrahydrofolate dehydrogenase isozyme expressed in adult tissues. J. Biol. Chem. 286, 5166-5174 (2011).
43. MacFarlane, A. J. et al. Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetrahydrofolate but is not essential in mice. J. Biol. Chem. 283, 25846-25853 (2008).
44. Mejia, N. R., MacKenzie, R. E. NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase in transformed cells is a mitochondrial enzyme. Biochem. Biophys. Res. Commun. 155, 1-6 (1988).
45. Krupenko, S. A., Oleinik, N. V. 10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells. Cell Growth Differ. 13, 227-236 (2002).
46. Anguera, M. C. et al. Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. J. Biol. Chem. 281, 18335-18342 (2006).
47. Krupenko, N. I. et al. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J. Biol. Chem. 285, 23056-23063 (2010).
48. Sena, L. A., Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48, 158-167 (2012).
49. Liou, G. Y., Storz, P. Reactive oxygen species in cancer. Free Radic. Res. 44, 479-496 (2010).
50. Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186-191 (2015).
51. Porporato, P. E. et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8, 754-766 (2014).
52. Porporato, P. E., Payen, V. L., Baselet, B., Sonveaux, P. Metabolic changes associated with tumor metastasis, part 2: mitochondria, lipid and amino acid metabolism. Cell. Mol. Life Sci. 73, 1349-1363 (2015).
53. Subramani, R. et al. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci. Rep. 6, 19819 (2016).
54. Cheung, E. C. et al. Opposing effects of TIGAR-and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes Dev. 30, 52-63 (2016).
55. Gorrini, C., Harris, I. S., Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931-947 (2013).
56. Jiang, L. et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255-258 (2016).
57. Ye, J. et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4, 1406-1417 (2014).
58. Ost, M. et al. Muscle mitohormesis promotes cellular survival via serine/glycine pathway flux. FASEB J. 29, 1314-1328 (2015).
59. Mehrmohamadi, M., Liu, X., Shestov, A. A., Locasale, J. W. Characterization of the usage of the serine metabolic network in human cancer. Cell Rep. 9, 1507-1519 (2014).
60. Struck, A. W., Thompson, M. L., Wong, L. S., Micklefield, J. S-Adenosyl-methionine-dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. Chembiochem 13, 2642-2655 (2012).
61. Kinnaird, A., Zhao, S., Wellen, K. E., Michelakis, E. D. Metabolic control of epigenetics in cancer. Nat. Rev. Cancer https://dx.doi.org/10.1038/nrc.2016.82 (2016).
62. Sunden, S. L., Renduchintala, M. S., Park, E. I., Miklasz, S. D., Garrow, T. A. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch. Biochem. Biophys. 345, 171-174 (1997).
63. Scott, J. M., Weir, D. G. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of subacute combined degeneration in pernicious anaemia. Lancet 2, 337-340 (1981).
64. Maddocks, O. D., Labuschagne, C. F., Adams, P. D., Vousden, K. H. Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol. Cell 61, 210-221 (2016).
65. Mentch, S. J. et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 22, 861-873 (2015).
66. Hardie, D. G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25, 1895-1908 (2011).
67. Ballatori, N. et al. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem. 390, 191-214 (2009).
68. Hultberg, B., Hultberg, M. High glutathione turnover in human cell lines revealed by acivicin inhibition of gamma-glutamyltranspeptidase and the effects of thiol-reactive metals during acivicin inhibition. Clin. Chim. Acta 349, 45-52 (2004).
69. DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475-1481 (2015).
70. Gruning, N. M. et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 14, 415-427 (2011).
71. Anastasiou, D. et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011).
72. Snell, K. Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv. Enzyme Regul. 22, 325-400 (1984).
73. Snell, K., Natsumeda, Y., Eble, J. N., Glover, J. L., Weber, G. Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma. Br. J. Cancer 57, 87-90 (1988).
74. Pollari, S. et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res. Treat. 125, 421-430 (2011).
75. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011).
76. Mullarky, E., Mattaini, K. R., Vander Heiden, M. G., Cantley, L. C., Locasale, J. W. PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell Melanoma Res. 24, 1112-1115 (2011).
77. Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869-874 (2011).
78. Antonov, A. et al. Bioinformatics analysis of the serine and glycine pathway in cancer cells. Oncotarget 5, 11004-11013 (2014).
79. Pacold, M. E. et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat. Chem. Biol. 12, 452-458 (2016).
80. Liu, J. et al. Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J. Neurooncol. 111, 245-255 (2013).
81. Fan, J. et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem. Biol. 10, 510-516 (2015).
82. Yoon, S. et al. Clinical implication of serine metabolism-associated enzymes in colon cancer. Oncology 89, 351-359 (2015).
83. Gylfe, A. E. et al. Eleven candidate susceptibility genes for common familial colorectal cancer. PLoS Genet. 9, e1003876 (2013).
84. Peters, J. M., Shah, Y. M., Gonzalez, F. J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat. Rev. Cancer 12, 181-195 (2012).
85. Ericsson, A., Turner, N., Hansson, G. I., Wallenius, K., Oakes, N. D. Pharmacological PPAR activation markedly alters plasma turnover of the amino acids glycine, serine and arginine in the rat. PLoS ONE 9, e113328 (2014).
86. Nilsson, L. M. et al. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet. 8, e1002573 (2012).
87. Field, M. S. et al. Nuclear enrichment of folate cofactors and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) protect de novo thymidylate biosynthesis during folate deficiency. J. Biol. Chem. 289, 29642-29650 (2014).
88. MacFarlane, A. J., McEntee, M. F., Stover, P. J. Azoxymethane-induced colon carcinogenesis in mice occurs independently of de novo thymidylate synthesis capacity. J. Nutr. 144, 419-424 (2014).
89. Macfarlane, A. J., Perry, C. A., McEntee, M. F., Lin, D. M., Stover, P. J. Shmt1 heterozygosity impairs folate-dependent thymidylate synthesis capacity and modifies risk of Apc(min)-mediated intestinal cancer risk. Cancer Res. 71, 2098-2107 (2011).
90. Anderson, D. D., Woeller, C. F., Chiang, E. P., Shane, B., Stover, P. J. Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J. Biol. Chem. 287, 7051-7062 (2012).
91. Field, M. S., Kamynina, E., Watkins, D., Rosenblatt, D. S., Stover, P. J. Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis. Proc. Natl Acad. Sci. USA 112, 400-405 (2015).
92. MacFarlane, A. J., Perry, C. A., McEntee, M. F., Lin, D. M., Stover, P. J. Mthfd1 is a modifier of chemically induced intestinal carcinogenesis. Carcinogenesis 32, 427-433 (2011).
93. Lee, G. Y. et al. Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Res. 74, 3114-3126 (2014).
94. Gustafsson Sheppard, N. et al. The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation. Sci. Rep. 5, 15029 (2015).
95. Lehtinen, L. et al. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 4, 48-63 (2013).
96. Valencia, T. et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26, 121-135 (2014).
97. Bollig-Fischer, A., Dewey, T. G., Ethier, S. P. Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells. PLoS ONE 6, e17959 (2011).
98. Jun, D. Y. et al. Positive regulation of promoter activity of human 3-phosphoglycerate dehydrogenase (PHGDH) gene is mediated by transcription factors Sp1 and NF-Y. Gene 414, 106-114 (2008).
99. Ding, J. et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab. 18, 896-907 (2013).
100. Wu, K. C., Cui, J. Y., Klaassen, C. D. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol. Sci. 123, 590-600 (2011).
101. Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79 (2012).
102. Zhao, E. et al. KDM4C and ATF4 cooperate in transcriptional control of amino acid metabolism. Cell Rep. 14, 506-519 (2016).
103. Berry, W. L., Janknecht, R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 73, 2936-2942 (2013).
104. Riscal, R. et al. Chromatin-bound MDM2 regulates serine metabolism and redox homeostasis independently of p53. Mol. Cell 62, 890-902 (2016).
105. Moran, D. M. et al. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol. Cancer Ther. 13, 1611-1624 (2014).
106. Audet-Walsh, E. et al. The PGC-1/ERR axis represses one-carbon metabolism and promotes sensitivity to anti-folate therapy in breast cancer. Cell Rep. 14, 920-931 (2016).
107. Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J., Asara, J. M., Manning, B. D. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351, 728-733 (2016).
108. Ma, L. et al. Control of nutrient stress-induced metabolic reprogramming by PKC in tumorigenesis. Cell 152, 599-611 (2013).
109. Ou, Y., Wang, S. J., Jiang, L., Zheng, B., Gu, W. p53 protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation. J. Biol. Chem. 290, 457-466 (2015).
110. Amelio, I. et al. p73 regulates serine biosynthesis in cancer. Oncogene 33, 5039-5046 (2014).
111. Melino, G., De Laurenzi, V., Vousden, K. H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2, 605-615 (2002).
112. Kruiswijk, F., Labuschagne, C. F., Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393-405 (2015).
113. Labuschagne, C. F., van den Broek, N. J., Mackay, G. M., Vousden, K. H., Maddocks, O. D. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 7, 1248-1258 (2014).
114. Zhang, W. C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272 (2012).
115. Kim, D. et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520, 363-367 (2015).
116. Azize, N. A. et al. Mutation analysis of glycine decarboxylase, aminomethyltransferase and glycine cleavage system protein-H genes in 13 unrelated families with glycine encephalopathy. J. Hum. Genet. 59, 593-597 (2014).
117. Vousden, K. H., Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
118. Start, K. Treating phenylketonuria by a phenylalanine-free diet. Prof. Care Mother Child 8, 109-110 (1998).
119. Hayashi, S., Tanaka, T., Naito, J., Suda, M. Dietary and hormonal regulation of serine synthesis in the rat. J. Biochem. 77, 207-219 (1975).
120. Gravel, S. P. et al. Serine deprivation enhances antineoplastic activity of biguanides. Cancer Res. 74, 7521-7533 (2014).
121. Mullarky, E. et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc. Natl Acad. Sci. USA 113, 1778-1783 (2016).
122. Chen, J. et al. Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth. Oncotarget 4, 2502-2511 (2013).
123. Rose, M. L. et al. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis 20, 2075-2081 (1999).
124. Rose, M. L., Madren, J., Bunzendahl, H., Thurman, R. G. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis 20, 793-798 (1999).
125. Locasale, J. W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13, 572-583 (2013).
126. Gonen, N., Assaraf, Y. G. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. 15, 183-210 (2012).
127. Longley, D. B., Harkin, D. P., Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338 (2003).
128. Huennekens, F. M. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv. Enzyme Regul. 34, 397-419 (1994).
129. Valik, D., Radina, M., Sterba, J., Vojtesek, B. Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics 5, 1151-1162 (2004).
130. Dervieux, T., Greenstein, N., Kremer, J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54, 3095-3103 (2006).
131. Chang, C., Pearce, E. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17, 364-368 (2016).
132. Sharma, P., Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).